Intended for US Audiences Only

 

Connect With Us

    Discover IXINITY for the treatment of hemophilia B.

    What is IXINITY?

    IXINITY® [coagulation factor IX (recombinant)] is a medicine used to replace clotting factor (factor IX) that is missing in adults and children at least 12 years of age with hemophilia B. Hemophilia B is also called congenital factor IX deficiency or Christmas disease. Hemophilia B is an inherited bleeding disorder that prevents clotting. Your healthcare provider may give you IXINITY for routine prophylaxis, for on demand treatment to prevent bleeding episodes or when you have surgery.

    IXINITY is not indicated for induction of immune tolerance in patients with hemophilia B.

    IXINITY allows you to define your IXperience.

    No longer are people with hemophilia B defined by their condition—they’re defined by their abilities and their passions.

    IXINITY is a blood-clotting medicine for hemophilia B. IXINITY has an average incremental recovery of 98%.1 Higher recovery may allow lower doses. IXINITY also has a terminal half-life of 24 hours,1 which allows for peak factor levels when you need them.

    A different IXperience for people with hemophilia B.

    John Taylor’s Hemophilia B Journey

    The founder of the Coalition for Hemophilia B and the father of a son with hemophilia B shares his inspiring story of hope.

    Medexus Pharma

    Making connections that matter.

    At Medexus, we take pride in our patient-first philosophy that focuses on improving people’s lives through a personalized approach that helps us understand people’s needs and a passion for creating solutions that align with their goals.

    Learn more about Medexus Pharma.

    Reference: 1. IXINITY [coagulation factor IX (recombinant)] prescribing information. Chicago, IL: Medexus Pharma, Inc.; November 2022

    Call 1-855-IXINITY (1-855-494-6489) to speak with your IXperience™ Concierge for more information on IXINITY.

    Medexus Pharma, Inc., Chicago, IL 60606

    IXINITY [coagulation factor IX (recombinant)] and any and all Medexus Pharma, Inc. brand, product, service and feature names, logos, and slogans are trademarks or registered trademarks of Medexus Pharma, Inc. in the United States and/or other countries.

    ©2023 Medexus Pharma, Inc.
    All rights reserved. MP-IX-0334

    INDICATIONS AND IMPORTANT SAFETY INFORMATION

    Expand

    What is IXINITY?

    IXINITY [coagulation factor IX (recombinant)] is a medicine used to replace clotting factor (factor IX) that is missing in adults and children at least 12 years of age with hemophilia B. Hemophilia B is also called congenital factor IX deficiency or Christmas disease. Hemophilia B is an inherited bleeding disorder that prevents clotting. Your healthcare provider may give you IXINITY for routine prophylaxis, for on demand treatment to control bleeding episodes or when you have surgery.

    IXINITY is not indicated for induction of immune tolerance in patients with hemophilia B.

    IMPORTANT SAFETY INFORMATION for IXINITY

    • You should not use IXINITY if you are allergic to hamsters or any ingredients in IXINITY.

    • You should tell your healthcare provider if you have or have had medical problems, take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies, have any allergies, including allergies to hamsters, are nursing, are pregnant or planning to become pregnant, or have been told that you have inhibitors to factor IX.

    • You can experience an allergic reaction to IXINITY. Contact your healthcare provider or get emergency treatment right away if you develop a rash or hives, itching, tightness of the throat, chest pain, or tightness, difficulty breathing, lightheadedness, dizziness, nausea, or fainting.

    • Your body may form inhibitors to IXINITY. An inhibitor is part of the body's defense system. If you develop inhibitors, it may prevent IXINITY from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for development of inhibitors to IXINITY.

    • If you have risk factors for developing blood clots, the use of IXINITY may increase the risk of abnormal blood clots.

    • Call your healthcare provider right away about any side effects that bother you or do not go away, or if your bleeding does not stop after taking IXINITY.

    • The most common side effect that was reported with IXINITY during clinical trials was headache.

    • These are not all the side effects possible with IXINITY. You can ask your healthcare provider for information that is written for healthcare professionals.


    For more information about IXINITY, please see full Prescribing Information, including Important Patient Information.

    You are encouraged to report adverse events related to Medexus Pharma products by calling 1-844-859-6675. If you prefer, you may contact the Food and Drug Administration directly. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.